Addressing Immune Checkpoint Resistance in Glioma with Dual-Siglec Inhibition

• Unité de recherche: INNOSUISSE
• Numéro de projet: 124.137 IP-LS
• Titre du projet anglais: Addressing Immune Checkpoint Resistance in Glioma with Dual-Siglec Inhibition

Mots-clé (Anglais)

Life sciences, Pharmaceuticals

Résumé des résultats (Abstract) (Anglais)

Glioblastomas are aggressive brain tumors currently not amenable to checkpoint inhibitor therapy. Our dual acting inhibitors aim to overcome immune suppression thus restoring or inducing anti-tumor immunity and improving patient outcomes.